Emerging treatment strategies improve mortality and disease-free survival in aplastic anemia, highlighting advances in hematopoietic cell transplant and immunosuppressive treatment.
Key Points
Improved overall survival and disease-free survival rates in patients after hematopoietic cell transplant for aplastic anemia have been observed.
Clinical trials support the use of innovative graft-versus-host disease prophylaxis to lessen morbidity and mortality.
The introduction of reduced-toxicity conditioning regimens may enable more patients to receive hematopoietic cell transplants from alternative donors.
These advances suggest a significant paradigm shift in the treatment of aplastic anemia, especially in treatment-naive patients.